Sarepta gene therapy study missed key target in Duchennes, page-411

I don't think so.

I think looking at as competitive drugs is wrong. They are completely different drugs, that attack the problem of DMD differently. In fact we have data that shows the drugs may work in a complimentary fashion.

Jumping up and down over this sarepta drug would be bad form, particularly to the families of the DMD boys.

I would mush prefer that management just concentrate on progressing our drug. Results equal to or better than our last trial is all we need. The way the FDA have dealt with Sarepta shows that would be more than enough for an approval.